Department of Interventional Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Biosci Trends. 2021 May 11;15(2):100-106. doi: 10.5582/bst.2021.01016. Epub 2021 Mar 12.
Hepatocellular carcinoma (HCC) remains a major public health problem. MCM4, a constitutive member of the minichromosomal maintenance protein family, has been reported to play a vital role in cancer malignancy behavior. However, the function of MCM4 in HCC remains largely unknown. The present study explored the specific role of MCM4 in HCC. The data from public datasets including TCGA and GTEx showed that MCM4 was overexpressed in HCC and significantly associated with poor prognosis. Immunohistochemistry results from 102 HCC patients suggested that high-level expression of MCM4 was correlated with tumor size. Then a series of in vivo and in vitro experiments were performed to investigate the function of MCM4 in HCC tumor cells. MCM4 silencing suppressed the cell proliferation and sphere formation of hepatoma cells. Moreover, silencing MCM4 significantly decreased the growth of tumors in a xenograft tumor model. In conclusion, the results of the present study indicated that MCM4 was a potential prognostic predictor associated with poor outcomes of HCC patients and even a therapeutic target for HCC.
肝细胞癌 (HCC) 仍然是一个主要的公共卫生问题。MCM4 是微小染色体维持蛋白家族的组成成员,据报道在癌症恶性行为中发挥着重要作用。然而,MCM4 在 HCC 中的功能在很大程度上尚不清楚。本研究探讨了 MCM4 在 HCC 中的特定作用。来自 TCGA 和 GTEx 等公共数据集的数据表明,MCM4 在 HCC 中过度表达,并且与不良预后显著相关。来自 102 名 HCC 患者的免疫组化结果表明,MCM4 的高表达与肿瘤大小相关。然后进行了一系列体内和体外实验来研究 MCM4 在肝癌细胞中的功能。沉默 MCM4 抑制了肝癌细胞的增殖和球体形成。此外,沉默 MCM4 显著降低了异种移植肿瘤模型中肿瘤的生长。总之,本研究结果表明,MCM4 是与 HCC 患者不良预后相关的潜在预后预测因子,甚至是 HCC 的治疗靶点。